Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus Tissue Repair Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.lotustissuerepair.com

Latest From Lotus Tissue Repair Inc.

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

Clinical Trials Regulation

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

BioPharmaceutical United States

Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge

Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.

BioPharmaceutical United States

2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A

According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Mark de Souza, PhD, Pres. & CEO
    James Fordyce, EVP, CFO
    Philip Reilly, MD, Interim CMO
  • Contact Info
  • Lotus Tissue Repair Inc.
    Phone: (617) 674-7610
    1 Mifflin Pl.
    Ste. 400
    Cambridge, MA 02138
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register